TransCode Therapeutics, Inc
Price
FilingsNewest: 8-K, Material agreementOct 1 →InsidersNo open-market buys or sales.→HoldersYorkville Advisors Global 1.9%Vanguard 0.6%Vanguard Fiduciary Trust 0.3%→Financing →PeersClosest companies: SNTI, JSPR, CNSP→
From the filings
Figures
- Net income
- −$42.8Mlast 12 months
- Operating cash flow
- −$21.4Mlast 12 months
- Cash and equivalents
- $8.4Mat the last balance sheet
- Shares outstanding
- 1.0M shareson issue